Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation

Leukemia

Volumn 16, Issue 11, 2002, Pages 2259-2266

  Pascal, V ^a   Brunet, C ^b   Pradel, V ^d   Thirion, X ^d   Andre, P ^f   Faucher, C ^c   Sampol, J ^b   Dignat George, F ^b   Blaise, D ^c   Vivier, E ^a,b,e   Chabannon, C ^c  

^a INSERM   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e INSTITUT UNIVERSITAIRE DE FRANCE   (France)

^f INNATE PHARMA   (France)

Author keywords

Cell therapy; MHC matched allogeneic transplantation; NK cells; T cells

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ANTIGEN SPECIFICITY; APHERESIS; ARTICLE; BONE MARROW; CELL COUNT; CELL SURFACE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; MALE; MORBIDITY; NATURAL KILLER CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T LYMPHOCYTE;

EID: 0036849323     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402670     Document Type: Article

References (50)

1. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, Lerner KG, Glucksberg H, Buckner CD. Bone-marrow transplantation. N Engl J Med 1975; 292: 832-843 (part 1) and 895-902 (part II).
2. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Sanders J, Singer J, Stewart P, Thomas ED. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
3. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P, Sanders JE, Singer J, Thomas ED. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320: 828-834.
4. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-1198.
5. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, Bock G, Gassner C, Schiller L, Petersen F, Niederwieser D. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-1508.
6. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
7. Kernan NA. T-cell depletion for the prevention of graft-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Stem Cell Transplantation. Blackwell Science: Oxford, 1999, pp 186-196.
8. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340: 1704-1714.
9. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995; 345: 1144-1146.
10. Drobyski WR, Majewski D, Hanson G. Graft-facilitating doses of ex vivo activated gammadelta, T cells do not cause lethal murine graft-vs.-host disease. Biol Blood Marrow Transplant 1999; 5: 222-230.
11. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187-376.
12. Bennett M. Biology and genetics of hybrid resistance. Adv Immunol 1987; 41: 333-445.
13. Murphy WJ, Longo DL. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol Rev 1997; 157: 167-176.
14. Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998; 101: 1835-1842.
15. Koh CY, Welmak LA, Murphy WJ. Adoptive cellular immunotherapy: NK cells and bone marrow transplantation. Histol Histopathol 2000; 15: 1201-1210.
16. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. Receptors for HLA class-I molecules in human natural killer cells. Ann Rev Immunol 1996; 14: 619-648.
17. Lanier L. On guard-activating NK cell receptors. Nat Immunol 2001; 2: 23-27.
18. Long EO. Regulation of immune responses through inhibitory receptors. Ann Rev Immunol 1999; 17: 875-904.
19. Moretta A, Bottino C, Vitale M, Pencle D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Ann Rev Immunol 2001; 19: 197-223.
20. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-133.
21. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001; 31: 1076-1086.
22. Mandelboim O, Lieberman N, Lev M, Paul L, Amon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409: 1055-1060.
23. Cambiaggi A, Verthuy C, Naquet P, Romagne F, Ferrier P, Biassoni R, Moretta A, Moretta L, Vivier E. Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor. Proc Natl Acad Sci USA 1997; 94: 8088-8092.
24. Koh CY, Blazar BR, George T, WeIniak LA, Capitini CM, Raziuddin A, Murphy WJ, Bennett M. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001; 97: 3132-3137.
25. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
26. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassom F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
27. Karre K. Immunology. A perfect mismatch. Science 2002; 295: 2029-2031.
28. Zeis M, Uharek L, Glass B, Steinmann J, Dreger P, Gassmann W, Schmitz N. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice. Br J Haematol 1997; 96: 757-761.
29. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001; 98: 11521-11526.
30. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-171.
31. Blaise D, Jourdan E, Michallet M, Jouet JP, Boiron JM, Michel G, Faucher C, Fegueux N, Schuller ME, Badri N, Chabannon C, Maraninchi D. Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study. Bone Marrow Transplant 1998; 22: 1153-1158.
32. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, Jouet JP, Attal M, Bordigoni P, Cahn JY, Boiron JM, Schuller ME, Moatti JP, Michallet M. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe cle Moelle. J Clin Oncol 2000; 18: 537-546.
33. Olivero S, Alario T, Laclaique P, Haccoun M, Viens P, Blaise D, Chabannon C. CD34+ cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol. Bone Marrow Transplant 1999; 23: 387-394.
34. Andre P, Biassoni R, Colonna M, Cosman D, Lanier LL, Long EO, Lopez-Botet M, Moretta A, Moretta L, Parham P, Trowsdale J, Vivier E, Wagtmann N, Wilson MJ. New nomenclature for MHC receptors. Nat Immunol 2001; 2: 661.
35. Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Bourquelot P, Greinix H, Frickhofen N, Ringden O, Zander A, Apperley JF, Gorin C, Borkett K, Schwab G, Goebel M, Russell NH, Gratwohl A. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003.
36. Vigorito AC, Azevedo WM, Marques JF, Azevedo AM, Eid KA, Aranha FJ, Lorand-Metze I, Oliveira GB, Correa ME, Reis AR, Miranda EC, de Souza CA. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145-1151.
37. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, Shepherd V, Rowland A, Sirohi B, Tait D, Horton C, Long S, Singhal S. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231-1237.
38. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640.
39. Andre P, Spertini O, Guia S, Rihet P, Dignat-George F, Brailly H, Sampol J, Anderson PJ, Vivier E. Modification of P-selectin glyco-protein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin. Proc Nad Acad Sci USA 2000; 97: 3400-3405.
40. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de La Rubia J, Brunet S, Perez-Oteiza J, Ferra C, Zuazu J, Caballero D, Carvalhais A, Diez JL, Espigado I, Martinez C, Campilho F, Sanz MA, Sierra J, Garcia-Conde J, Montserrat E. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-387.
41. Williams NS, Kubota A, Bennett M, Kumar V, Takei F. Clonal analysis of NK cell development from bone marrow progenitors in vitro: orderly acquisition of receptor gene expression. Eur J Immunol 2000; 30: 2074-2082.
42. Roth C, Carlyle JR, Takizawa H, Raulet DH. Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC. Immunity 2000; 13: 143-153.
43. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. My Immunol 2000; 74: 181-273.
44. Maenaka K, Juji T, Nakayama T, Wyer JR, Gao GF, Maenaka T, Zaccai NR, Kikuchi A, Yabe T, Tokunaga K, Tadokoro K, Stuart DI, Jones EY, Van Der Merwe PA. Killer cell Immunoglobulin receptors and T cell receptors bind peptide- major histocompatibility complex class I with distinct Thermodynamic and kinetic properties. J Biol Chem 1999; 274: 28329-28334.
45. Liberatore C Capanni M, Albi N, Volpi I, Urbani E, Ruggeri L, Mencarelli A, Grignani F, Velardi A. Natural killer cell-mediated lysis of autologous cells modified by gene therapy. J Exp Med 1999; 189: 1855-1862.
46. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gammadelta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-6884.
47. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol 2002; 14: 306-311.
48. Lister J, Rybka WB, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ, Elder EM, Ball ED, Whiteside TL. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate post-transplant period. Clin Cancer Res 1995; 1: 607-614.
49. deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W, Whiteside T, Ball E. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother 2000; 23: 154-160.
50. Pascal V, Vivier E, André P. CD158 (killer immunoglobulin-like receptors family) report. In: Mason D, André P, Bensussan A, Buckley C, Civin C, Clark E, de Hass M, Goyert S, Hadam M, Hart D, Horejsi V, Jones Y, Meuer S, Morrissey J, Schwartz-Albiez R, Shaw S, Simmons D, Turni L, Uguccioni M, van der Schoot M, Vivier E, Zola H (eds). Leucocyte Typing VII. White Cell Differentiation Antigens. Oxford University Press: Oxford, 2002, pp 412-413.